Results 1 to 10 of about 4,657 (129)

ARIA in Patients Treated With Lecanemab (BAN2401) in a Phase 2 Study in Early Alzheimer's Disease

Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023
INTRODUCTION Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques.
Lawrence S Honig, Jerome Barakos, Michio Kanekiyo   +2 more
exaly   +2 more sources

Caregiver positivity as a psychosocial modifier of lecanemab-related outcomes in Alzheimer's disease: A multicenter longitudinal study in China. [PDF]

Alzheimers Dement
Abstract INTRODUCTION Real‐world modifiers of lecanemab benefit in Alzheimer's disease (AD) remain elusive. We examined associations between caregiver positivity and longitudinal outcomes in AD. METHODS This seven‐center longitudinal study followed 127 biomarker‐supported AD patient–caregiver dyads over 18 months.
Wu W, Liu H, Liang Y, Li H, Zhang J, Sun Z, Song Y, Fei M, Wu H, Jiang M, Fan S, Zhou C, Cao Y, Chen H, Liu S.   +14 more
europepmc   +2 more sources

Use of Lecanemab for the Treatment of Alzheimer's Disease: A Systematic Review

Brain and Behavior
Purpose The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer's disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the studies that are ...
Md Fahad Hossain
exaly   +2 more sources

Safety and Efficacy of Lecanemab for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Frontiers in Aging Neuroscience, 2023
ObjectiveWe performed a systematic review and meta-analysis of the cognitive effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD).MethodsWe screened the literature published before February 2023 in PubMed, Embase, Web of ...
Yuewei Chi, Yue Qiao
exaly   +3 more sources

Real‐world evidence for amyloid‐targeted therapies: Lecanemab and donanemab [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Real‐world safety data on amyloid‐targeted therapies in early Alzheimer's disease remain limited, particularly for modified donanemab titration and direct lecanemab–donanemab comparisons.
Ryan Hakim, Kristofer Harris, Livia Merrill, Amanda Falk‐Vargas, Eileen Whalen, Tianxu Xia, Olga Ochoa, David Hunter, Paul Ernest Schulz   +8 more
doaj   +2 more sources

Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer’s disease: a target trial emulation [PDF]

Alzheimer’s Research & Therapy
Background Acetylcholinesterase inhibitors (AChEIs) provide symptomatic relief in Alzheimer’s disease (AD), whereas lecanemab may modify disease progression; however, real-world evidence on its safety and clinical impact remains limited.
Chuo-Yu Lee, Chih-Wei Hsu, Ping-Tao Tseng, Yi-Ya Fang, Brendon Stubbs, Trevor Thompson, Andre F. Carvalho, Yu-Hsuan Lin, Yu-Chen Kao, Fu-Chi Yang, Tien-Wei Hsu, Chih-Sung Liang   +11 more
doaj   +2 more sources

Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not? [PDF]

Alzheimers Dement
Abstract In the future, treatment of dementia will be personalized, targeted to contributing pathologies, rather than the clinical syndrome. Anti‐amyloid drugs for Alzheimer's disease are the first approved drugs; however, the impact of co‑pathology on the treatment effects remains incomplete.
Exalto L, van Alphen J, Barkhof F, Teunissen C, Vijverberg E, Aarsland D, Lemstra A.   +6 more
europepmc   +2 more sources

Real‐world implementation of lecanemab in Alzheimer's disease: A Japanese cohort [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Real‐world evidence for lecanemab remains limited, particularly among Asian populations. We evaluated the feasibility, safety, biomarker profiles, and short‐term clinical outcomes of lecanemab in practice in Japan.
Sho Shimohama, Shogyoku Bun, Ryo Shikimoto, Hiroi Tomioka, Toshiki Takayama, Yu Mimura, Hiroki Sasaguri, Koji Sekiguchi, Yoshinori Nishimoto, Yu Iwabuchi, Hajime Tabuchi, Jin Nakahara, Masaru Mimura, Daisuke Ito   +13 more
doaj   +2 more sources

Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology [PDF]

Frontiers in Psychiatry
IntroductionLecanemab is a monoclonal antibody targeting amyloid-beta (Aβ) approved for treating Alzheimer’s disease (AD) with mild cognitive impairment or mild dementia. Continuous monitoring of its real-world safety profile remains essential.
Xiaoxuan Xing, Ke Wang, Yingnan Feng, Chao Wu, Lihua Jia, Huiying Li, Zhiyong Wen, Yinan Tang, Zhizhou Wang, Xiaotong Zhang, Xiaoxi Li, Yiming Hua, Lan Zhang, Xianzhe Dong   +13 more
doaj   +2 more sources

Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study [PDF]

Therapeutic Advances in Drug Safety
Background: Anti-β-amyloid monoclonal antibodies provide a disease-modifying treatment approach for Alzheimer’s disease, but post-marketing safety concerns remain, particularly amyloid-related imaging abnormalities (ARIA).
Wei-Yang Xue, Xi Li, Wen-Ting Li, Bao-Zhi Qin, Cong-Zhi Wang, Tao Liu, Min Wang   +6 more
doaj   +2 more sources